Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does DABIGATRAN ETEXILATE Cause Haemoptysis? 294 Reports in FDA Database

Lower Your Cholesterol — The Natural Way

The Oxidized Cholesterol Strategy: a science-backed plan for heart health.

See the Strategy

According to the FDA Adverse Event Reporting System (FAERS), 294 reports of Haemoptysis have been filed in association with DABIGATRAN ETEXILATE (dabigatran etexilate). This represents 0.8% of all adverse event reports for DABIGATRAN ETEXILATE.

294
Reports of Haemoptysis with DABIGATRAN ETEXILATE
0.8%
of all DABIGATRAN ETEXILATE reports
66
Deaths
228
Hospitalizations

How Dangerous Is Haemoptysis From DABIGATRAN ETEXILATE?

Of the 294 reports, 66 (22.4%) resulted in death, 228 (77.6%) required hospitalization, and 33 (11.2%) were considered life-threatening.

Is Haemoptysis Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for DABIGATRAN ETEXILATE. However, 294 reports have been filed with the FAERS database.

What Other Side Effects Does DABIGATRAN ETEXILATE Cause?

Gastrointestinal haemorrhage (4,081) Cerebrovascular accident (2,175) Fall (1,786) Ischaemic stroke (1,581) Anaemia (1,412) Haemorrhage (1,324) Death (1,025) Rectal haemorrhage (964) Cerebral haemorrhage (946) Upper gastrointestinal haemorrhage (861)

What Other Drugs Cause Haemoptysis?

RIVAROXABAN (1,961) ASPIRIN (1,255) APIXABAN (846) TREPROSTINIL (838) ALBUTEROL (652) CLOPIDOGREL BISULFATE (643) PREDNISONE (618) WARFARIN (555) ADALIMUMAB (472) TIOTROPIUM (462)

Which DABIGATRAN ETEXILATE Alternatives Have Lower Haemoptysis Risk?

DABIGATRAN ETEXILATE vs DABRAFENIB DABIGATRAN ETEXILATE vs DABRAFENIB\TRAMETINIB DABIGATRAN ETEXILATE vs DACARBAZINE DABIGATRAN ETEXILATE vs DACLATASVIR DABIGATRAN ETEXILATE vs DACLIZUMAB

Related Pages

DABIGATRAN ETEXILATE Full Profile All Haemoptysis Reports All Drugs Causing Haemoptysis DABIGATRAN ETEXILATE Demographics